Clinical Trials Logo

Poisoning clinical trials

View clinical trials related to Poisoning.

Filter by:

NCT ID: NCT04975867 Recruiting - Hypothermia Clinical Trials

Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning

Start date: October 25, 2021
Phase: N/A
Study type: Interventional

This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).

NCT ID: NCT04941859 Recruiting - Poisoning Patients Clinical Trials

Medicine Acuity Patching Combined Massage in the Treatment of Patients With Acute Poisoning

Start date: March 8, 2021
Phase: N/A
Study type: Interventional

This topic in western medicine combined on the basis of gastric lavage therapy in patients with acute poisoning acupoint sticking of traditional Chinese medicine and acupuncture point massage treatment, aims to smoothly accelerate cleaning and discharge poison, increase the poisoning patients rescue success rate, improve patient quality of life, for the clinical treatment of acute poisoning provides a new method of TCM nursing, to further exert TCM nursing characteristics.

NCT ID: NCT04925297 Not yet recruiting - Clinical trials for Carbon Monoxide Poisoning

Neurological Sequelae in Patients With Acute Carbon Monoxide Poisoning

Start date: August 1, 2021
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to access the clinical characteristics and risk factors for neurological sequelae after acute carbon monoxide poisoning.

NCT ID: NCT04877067 Completed - Clinical trials for Magnetic Field Exposure

Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation

Magnovision
Start date: April 1, 2019
Phase: Phase 3
Study type: Interventional

The axons of the retinal ganglion cells combine to form the optic nerve. The optic nerve transmits electrical signals to the visual cortex by various synapses. Optic nerve axons are more sensitive to toxins than retina because they are outside the blood retinal barrier. Methanol, various solvents and heavy metals, carbon dioxide, antiarrhythmic, antiepileptic, antibiotics and some vasoactive drugs can cause toxic optic neuropathy. There is a different pathophysiology for each toxin. Methanol is easily accessible alcohol in all types of disinfectants. Methanol is converted into formaldehyde and formic acid while metabolized in the liver. Formaldehyde disrupts ATP synthesis by blocking mitochondrial function and oxidative phosphorylation. Formic acid causes demyelination as a result of metabolic acidosis. Neuroinflammation occurs when denatured proteins block axoplasmic flow. All these processes can lead to apoptosis and permanent vision loss. Sildenafil is a vasoactive drug used in erectile dysfunction. Sildenafil decreases optic nerve head blood flow. Neuroinflammation develops secondary to the cessation of axoplasmic flow after hypoxia. If hypoxia and neuroinflammatiom persists, apoptosis and permanent vision loss develop. Amiodarone is an ion channel blocker used in the treatment of cardiac arrhythmias. Long-term use may cause disruption of ion channel balance in the optic nerve. This condition leads to asymmetric neuroinflammation and apoptosis. Wharton's jelly derived mesenchymal stem cells (WJ-MSC) can increase mitochondrial ATP synthesis with paracrine effects and suppress neuroinflammation with immunomodulatory effects. Repetitive electromagnetic stimulation (rEMS) can rearrange ion channel balances and axoplasmic flow. The aim of this prospective phase-3 clinical study is to investigate the effect of WJ-MSC and rEMS combination in the therapy of toxic optic neuropathies. This combination is the first study in the literature for the therapy of toxic optic neuropathies.

NCT ID: NCT04850014 Recruiting - Obesity Clinical Trials

PBPK Modelling Applied to Acetaminophen Poisoned Obese Children

IntoxPara
Start date: January 1, 2021
Phase:
Study type: Observational

Childhood obesity is increasing globally. Changes in body composition and physiology in obesity setting modify pharmacokinetic parameters and might increase the risk in case of poisoning. Acetaminophen is a drug often implied in poisoning in children population, especially in adolescent attempting suicide. In practice, clinicians use weight to assess intoxication severity, but depending on the weight chosen (actual weight, lean body weight, ideal weight,..) the severity assessment can change as well as medical care needed. In this context we hypothesize that a PBPK modelling would be helpful to predict toxic dosing in obese population and especially in obese adolescent or children. The primary objective of this study is to collect data related to acetaminophen-poisoned patient with at least one acetaminophen concentration sampling and whose clinical outcome is known in order to refine and validate such a PBPK model.

NCT ID: NCT04807634 Recruiting - Coma Clinical Trials

Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning

Start date: March 10, 2021
Phase: N/A
Study type: Interventional

Intravenous Lipid Emulsion in Improving Coma Of Antipsychotic drugs Acute Poisoning: A Randomized Controlled Trial in Poison Control Center of Ain Shams University Hospitals

NCT ID: NCT04747678 Enrolling by invitation - Covid19 Clinical Trials

Adverse Effects of Ivermectin Used in Egypt During COVID-19

Start date: February 3, 2021
Phase:
Study type: Observational [Patient Registry]

retrograde study of common and rare adverse effects of multiple doses of ivermectin used during the coivd 19 pandemic in egypt

NCT ID: NCT04729894 Not yet recruiting - Safety Issues Clinical Trials

Evaluating the Impact of a Safe Medication Storage Device

Start date: July 1, 2021
Phase: N/A
Study type: Interventional

Despite the initial success of the 1970s Poison Prevention Packaging Act, the incidence of pediatric medication poisonings in the United States remains high. Unintentional pediatric medication ingestions result in significant morbidity and are associated with substantial healthcare use and costs. A majority of these medication poisonings involve a caregivers' medication and are caused by modifiable unsafe storage behaviors. A better understanding of factors associated with pediatric poisonings and safe medication storage behaviors is needed to inform public health policy and develop targeted educational interventions. Furthermore, low-cost, scalable interventions that improve medication storage behaviors and reduce pediatric poisonings are necessary to address this ongoing preventable public health crisis. In preliminary experiments, a baseline evaluation of caregivers demonstrated that they are unlikely to have a locked medication storage device in their home, but would be willing to use a locked device if one was available. Additionally, a follow-up assessment indicated that a majority of caregivers had used their medication over a one-month period. The latter feasibility assessment supports both caregiver willingness to use a safe storage device and demonstrates that a storage device can improve medication storage behaviors in the short-term. Given these findings, we hypothesize that pediatric medication poisonings are due to improper storage, that medication storage behaviors are influenced by demographic and household specific factors, and that medication lockboxes improve safe medication storage behaviors and reduce pediatric poisonings. These hypotheses will be evaluated using the studies in the following Specific Aims: (1) to identify factors associated with pediatric poisonings, (2) to identify factors associated with medication storage behaviors, (3) to evaluate the effect of lockboxes on storage behaviors and pediatric poisonings. Should this exploratory study reveal factors associated with increased risk for pediatric poisoning or with safe medication storage, and should safe medication storage interventions improve modifiable storage behaviors or show a reduction in pediatric poisonings, the results will be used to inform targeted public health campaigns and to develop a low-cost, scalable national program for improving safe medication storage and reducing pediatric poisonings.

NCT ID: NCT04724655 Completed - Clinical trials for Aluminum Phosphide Poisoning

Paraffin Oil or Coconut Oil in Acute Aluminum Phosphide Poisoning

Start date: January 1, 2021
Phase: Early Phase 1
Study type: Interventional

The aim of the present study is to evaluate safety and efficacy of gastric lavage with paraffin oil or gastric lavage with coconut oil in management of acute Aluminum phosphide poisoning.

NCT ID: NCT04702906 Not yet recruiting - Clinical trials for Aluminum Phosphide Poisoning

Trimetazidine As a Potential Adjuvant Therapy in Acute Aluminum Phosphide Poisoning-induced Cardiotoxicity

Start date: February 2021
Phase: N/A
Study type: Interventional

The aim of the present study is to evaluate the potential adjuvant therapeutic effect of trimetazidine in treatment of acute AlP poisoning-induced cardiotoxicity.